The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats

Clinics

Volumn 65, Issue 9, 2010, Pages 885-894

  von Wilmsdorff, Martina ^a   Bouvier, Marie Luise ^a   Henning, Uwe ^a   Schmitt, Andrea ^b,c   Gaebel, Wolfgang ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Clozapine; Haloperidol; Leptin; Leptin receptor; Schizophrenia; Ziprasidone

Indexed keywords

CLOZAPINE; HALOPERIDOL; LEPTIN; LEPTIN RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE; ZIPRASIDONE;

ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DRUG EFFECT; EATING; EXPLORATORY BEHAVIOR; HYPOTHALAMUS; MALE; MOTOR ACTIVITY; RAT; TIME; WEIGHT GAIN; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; CLOZAPINE; EATING; EXPLORATORY BEHAVIOR; HALOPERIDOL; HYPOTHALAMUS; LEPTIN; MALE; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, WISTAR; RECEPTORS, LEPTIN; THIAZOLES; TIME FACTORS; WEIGHT GAIN;

EID: 78249242479     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322010000900012     Document Type: Article

References (56)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappellari JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999; 156: 1686-96.
2. Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antisychotic medications. Schizophr Bull. 2004; 30:229-40.
3. Warrington L, Lombardo I, Loebel A, Ice K. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. CNS Drugs. 2007; 21:835-49, doi: 10.2165/00023210-200721100-00004.
4. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003; 64:598-604, doi: 10.4088/JCP.v64n0516.
5. Theisen FM, Linden A, König IR, Martin M, Remschmidt H, Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm. 2003; 110: 111-21.
6. Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier PM et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double.blind study. J Clin Psychopharmacol. 2007; 27:662-6, doi: 10.1097/jcp.0b013e31815a8872.
7. Weston-Greene K, Huang XF, Han M, Deng C. The effects of antipsychotics on density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. Int J Neuropsychopharmacol. 2008; 11:827-35.
8. Houseknecht KL, Baile CA, Matteri RL, Spurlock ME. The biology of leptin; a review. J Animal Sci. 1998; 76:1405-20.
9. Cancello R, Tounian A, Poitou CH, Clément K. Adiposity signals, genetics and body weight regulation in humans. Diabetes Metab. 2004; 30:215-27, doi: 10.1016/S1262-3636(07)70112-X.
10. Chehab FF, Qiu J, Ogus S. The use of animal models to dissect the biology of leptin. Recent Prog Horm Res. 2004; 59:245-66, doi: 10.1210/rp.59.1.245.
11. Dhillo WS. Appetite regulation: an overview. Thyroid. 2007; 17: 433-45, doi: 10.1089/thy.2007.0018.
12. Funahashi H, Yada T, Suzuki R, Shioda S. Distribution, function and properties of leptin receptors in the brain. Int Rev Cytology. 2003; 224:1-27, doi: 10.1016/S0074-7696(05)24001-9.
13. Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP: Olanzapineinduced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology. 2009; 207:119-25, doi: 10.1007/s00213-009-1639-8.
14. Deng C, Weston-Green K, Huang XF: The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychoticinduced weight gain? Prog Neuropsycho-pharmacol Biol Psychiatry. 2010; 34:1-4, doi: 10.1016/j.pnpbp.2009.11.009.
15. Hägg S, Söderburg S, Ahrén B, Olsson T, Mjörndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry. 2001; 62:843-8, doi: 10. 4088/JCP.v62n1102.
16. Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry. 2004; 65:1335-42, doi: 10. 4088/JCP.v65n1007.
17. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger DA, Newcomer JW. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacol. 2005; 30:184-91, doi: 10.1038/sj. npp.1300563.
18. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes. 2002; 26:137-41, doi: 10.1038/sj.ijo.0801840.
19. McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry. 2001; 62(suppl 23):23-9.
20. Minet-Ringuet J, Even PC, Goubern M, Tomé D, de Beaurepaire R. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite. 2006; 46:254-62, doi: 10.1016/j.appet.2006.01.008.
21. Cooper GD, Harrold JA, Halford JCG, Goudie AJ. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:428-36, doi: 10.1016/j.pnpbp.2007.09.012.
22. Kapur S, Wadenberg ML, Remington G. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can J Psychiatry. 2000; 45:241-6.
23. Sprick U, von Wilmsdorff M, Bouvier ML, Gaebel W. Behavioral and hippocampal changes after prenatal invasive interventions with possible relevance to schizophrenia. Behav Brain Res. 2006; 172: 179-86, doi: 10. 1016/j.bbr.2006.03.014.
24. Madiehe AM, Schaffhauser AO, Braymer DH, Bray G, York DA. Differential expression of leptin receptor in high- and low-fat Osborne- Mendel and S5B/PI rats. Obesity Res. 2000; 8:467-74, doi: 10.1038/oby.2000.58.
25. Pillai A, Parikh V, Terry jr AV, Mahadik SP. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brains. J Psychiatric Res 2007; 41:372-86, doi: 10. 1016/j.jpsychires.2006.01.011.
26. Sharpe JK, Stedman TJ, Byrne NM, Wishart C, Hills AP. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry. 2006; 40:810-4.
27. Cooper GD, Harrold JA, Halford JC, Goudie AJ. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhance adiposity: implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:428-36, doi: 10.1016/j.pnpbp.2007.09.012.
28. Schmitt A, Zink M, Müller B, May B, Herb A, Jatzko A, et al. Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem Res. 2003; 28:235-41, doi: 10.1023/ A:1022325116309.
29. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B, et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity. 2006; 14:36-51, doi: 10.1038/oby.2006.6
30. Hartfield AW, Moore NA, Clifton PG. Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology. 2003; 167:115-22.
31. Yoshida H, Itsukaichi O, Saito H, Masuda Y, Itoh T. Toxicological study on rats fed haloperidol: 80 week chronic toxicity test. J Tox Sci. 1995; 20:37-46
32. Minet-Ringuet J, Even PC, Guesdon B, Tomé D, de Beaurepaire R. Effects of chronic neuroleptic treatments on nutrient selection, body weight and body composition in the male rat under dietary self-selection. Behav Brain Res. 2005; 163:204-11, doi: 10.1016/j.bbr.2005.05.004.
33. Lee MD and Clifton PG. Meal patterns of free feeding rats treated with clozapine, olanzapine or haloperidol. Pharmacol Biochem Behav. 2002; 71:147-54, doi: 10.1016/S0091-3057(01)00630-X.
34. Sanci V, Houle S, da Silva JN. No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment. Can J Physiol Pharmacol. 2002; 80:36-41, doi: 10.1139/y02-002.
35. Davoodi N, Kalinichev M, Clifton PG. Comparative effects of olanzapine and ziprasidone on hypophagia enhanced by histamine neurotransmission in the rat. Behav Pharmacol. 2008; 19:121-8, doi: 10.1097/FBP. 0b013e3282f62c66.
36. Fell M, Neill J, Anjum N, Peltola L, Marshall K. Investigation into the influence of a high fat diet on antipsychotic.induced weight gain in female rats. J Psychopharmacol. 2008; 22:182-6, doi: 10.1177/0269881107082287.
37. Terry AV, Hill WD, Parikh V, Waller JL, Evans DR, Mahadik SP. Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology. 2003; 28:300-9, doi: 10.1038/sj.npp.1300039.
38. Calapai G, Caputi AP. Nitric oxide and drinking behaviour. Regul Pept. 1996; 66:117-21, doi: 10.1016/0167-0115(96)00050-X.
39. Calapai G, Corica F, Allegra A, Corsonello A, Sautebin L, De Gregorio T, et al. Effects of intracerebroventricular leptin administration on food intake, body weight gain and diencephalic nitric oxide synthase activity in the mouse. Br J Pharmacol. 1998; 125:798-802, doi: 10.1038/sj.bjp.0702121.
40. Yang SJ and Denbow DM. Interaction of leptin and nitric oxide on food intake in broilers and leghorns. Physiol Behav. 2007; 92:651-7, doi: 10. 1016/j.physbeh.2007.05.009.
41. Minet Ringuet J, Even PC, Valet P, Carpéné C, Visentin V, Prévot D, et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry. 2007; 12:562-71, doi: 10.1038/sj.mp.4001948.
42. Fischer V, Schmitt U, Weigmann H, v Keller B, Reuss S, Hiemke C, et al. Chronical haloperidol and clozapine treatment in rats: differential RNA display analysis, behavioural studies and serum level determination. Prog Neuropsychopharmacol Biol Psychiatry. 1998; 22:1129-39, doi: 10. 1016/S0278-5846(98)00065-7.
43. Schmitt U, Dahmen N, Fischer V, Weigmann H, Rao ML, Reuss S, et al. Chronic oral haloperidol and clozapine in rats: a behavioural evaluation. Neuropsychobiol. 1999; 39:86-91, doi: 10.1159/000026566.
44. Sorge S. Der Einfluss des atypischen Neuroleptikums Clozapin auf das Verhalten und das Immunsystem der Ratte. Dissertation, München 2003.
45. Zvezdochkina NV, Muranova LN, Andrianov SS, Gainutdinov KhL, Golubev Al. Locomotor responses and neuron excitability in conditions of haloperidol blockade of dopamine in invertebrates and vertebrates. Neurosci Behav Physiol 2006; 36:21-7.
46. Huang AC, Shyu BC, Hsiao S. Dose-dependent dissociable effects of haloperidol on locomotion, appetitive responses, and consummatory behavior in water-deprived rats. Pharmacol Biochem Behav 2010; 95: 285-91.
47. Del Bel EA, Guimarães FS, Bermúdez-Echeverry M, Gomes MZ, Schiaveto-de-souza A, Padovan-Neto FE, et al. Role of nitric oxide on motor behavior. Cell Mol Neurobiol. 2005; 25:371-92, doi: 10.1007/s10571-005-3065-8.
48. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005; 19 Suppl 1:1-93.
49. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kühn M, Uhr M, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 1999; 156:312-14.
50. Hauner H, Röhrig K, Hebebrand J, Skurk Th. No evidence for a direct effect of clozapine on fat-cell formation and production of leptin and other fat-cell-derived factors. Mol Psychiatry. 2003; 8:258-59, doi: 10. 1038/sj.mp.4001246.
51. Jennings CA, Cluderay JE, Gartlon J, Cilia J, Lloyd A, Jones DN, et al. The effects of ziprasidone on regional c-Fos expression in the rat forebrain. Psychopharmacology. 2006; 184:13-20, doi: 10.1007/s00213-005-0222-1.
52. Jéquier E. Leptin signalling, adiposity, and energy balance. AnnNY Acad Sci. 2002; 967:379-88, doi: 10.1111/j.1749-6632.2002.tb04293.x.
53. Trayhurn P and Bing C. Appetite and energy balance signals from adipocytes. Phil Trans R Soc. 2006; 361:1237-49, doi: 10.1098/rstb.2006.1859.
54. Liu Z.J, Bian J, Endoh A. Obesity reduced the gene expressions of leptin receptors in hypothalamus and liver. Horm Metab Res. 2007; 39:489-94, doi: 10.1055/s-2007-981680.
55. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2c receptor and antipsychoticinduced weight gain-mechanisms and genetics. J Psychopharm. 2006; 20:15-8, doi: 10.1177/1359786806066040.
56. Baptista T and Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry. 2002; 47:742-9.